3 ways GLP-1 drugs could be getting better
A race is shaping up among drug manufacturers that are vying to roll out better options when it comes to weight-loss drugs.
A race is shaping up among drug manufacturers that are vying to roll out better options when it comes to weight-loss drugs.
At the American Diabetes Association meeting in New Orleans, market leader Eli Lilly and Co. asserted its dominance in the weight-loss market.
If fulfilled, the proposed agreements signal an end for some potential legal roadblocks to the development of the Citizens-Lebanon Water Supply Program.
The Allen Whitehill Clowes Ballroom is being built adjacent to Clowes Memorial Hall and the Schrott Center for the Arts.
After transforming the treatment of diabetes and weight loss, a growing body of research is raising the possibility that these drugs may help protect against cancer.
The travel center will feature a convenience store, gift shop, extensive food offerings and bathrooms, plus gas pumps and electric vehicle charging stations.
Trial patients who received the drug after surgery or radiation therapy experienced an 83% reduction in the risk of disease recurrence or death compared with those who received a placebo.
The organization has already raised $3.9 million for its campaign with gifts from Eli Lilly and Co. Foundation, United Way of Central Indiana and other groups.
BE-101, soon to be known as Optavant, is expected to be commercially available in the third quarter of this year after it receives full licensure from the U.S. Department of Agriculture.
An ever-increasing group of older Americans is discovering that retirement is no longer a permanent state.
Eli Lilly and Co. this month unveiled startling new data for an experimental weight-loss drug. The breakthrough also is prompting some doctors to urge caution.
Tens of millions of people are now taking the medications worldwide, turning what began as obesity and diabetes treatments into what could be modern medicine’s largest unplanned neuroscience experiments.
CVS Caremark will add Foundayo coverage on June 1 and resume covering Zepbound on Oct. 1.
The Indianapolis-based drugmaker said some trial participants saw a level of weight loss similar to what patients experience after bariatric surgery.
The Indianapolis drugmaker is purchasing Curevo Inc., LimmaTech Biologics AG and Vaccine Co. Inc. to expand its research and development efforts in infectious disease.
At Crispus Attucks High School, students have many career-prep options through the school’s health care pathways program.
Deal after deal, Eli Lilly and Co. is using the fruits of its success from developing blockbuster GLP-1 medicines to prepare for its next chapter and build a bridge over a looming patent cliff.
The Indianapolis-based company has announced the phased launch of Befrena, a monoclonal antibody injection for treating canine allergic and atopic dermatitis.
The facility is capable of accommodating pharmaceutical products and raw materials needing storage at 2 to 8 degrees Celsius.
The name BioHeartland was created to give Indiana “a more cohesive and unified way to share the state’s story with investors, companies, researchers and talent around the world,” officials said.